Form 4: Summit Therapeutics CEO Boosts Stake in Private Placement

Summit Therapeutics Co-CEO Robert W. Duggan acquired over 14 million shares of common stock in a private placement at $18.74 per share, signaling strong confidence.

Summary

• Robert W. Duggan, Co-Chief Executive Officer, Director, and 10% Owner of Summit Therapeutics Inc. (SMMT), acquired common stock.
• The transaction occurred on October 21, 2025, as part of a private placement.
• Duggan directly acquired 13,980,789 shares of common stock at a price of $18.74 per share.
• An additional 266,808 shares were acquired indirectly by the Mahkam Zanganeh Revocable Trust, with the spouse as trustee, at $18.74 per share.
• An immediate family member of the spouse also acquired 26,680 shares indirectly at $18.74 per share.
• The acquisitions were made pursuant to a definitive agreement dated October 21, 2025.
• The transaction is anticipated to close on or about October 23, 2025.
• Following these transactions, Duggan directly beneficially owns 570,073,879 shares of common stock.
• Indirect beneficial ownership includes 25,724,474 shares via the Mahkam Zanganeh Revocable Trust, 76,680 shares via an immediate family member of the spouse, 31,000 shares by the spouse, and 10,199,776 shares via the Shaun Zanganeh Irrevocable Trust.
• Duggan disclaims beneficial ownership of indirectly held securities except to the extent of his pecuniary interest.

Sentiment

Score: 9

Explanation: The significant acquisition of common stock by a key insider (Co-CEO, Director, and 10% owner) in a private placement indicates strong confidence in the company's valuation and future prospects.

Positives

• Significant insider buying by the Co-CEO, Director, and 10% owner, Robert W. Duggan, indicates strong confidence in the company's future prospects.
• The acquisition of 13,980,789 shares directly, along with additional indirect acquisitions, represents a substantial personal investment.
• The purchase price of $18.74 per share suggests management believes the stock is undervalued or fairly priced at this level.

Future Outlook

The private placement transaction is anticipated to close on or about October 23, 2025.

Industry Context

Insider purchases, especially by high-ranking executives and significant shareholders, are often viewed by the market as a strong signal of confidence in a company's future performance and intrinsic value. Such transactions can sometimes precede positive company developments or reflect a belief that the stock is undervalued.

Related Party Transactions

• The acquisition of common stock by Robert W. Duggan, who is the Co-Chief Executive Officer, a Director, and a 10% Owner, constitutes a related party transaction.

Stakeholder Impact

• Shareholders may view this significant insider purchase as a strong vote of confidence from management, potentially leading to increased investor interest and positive sentiment.
• The capital raised through the private placement could provide additional funding for company operations or strategic initiatives.

Next Steps

• The private placement transaction is anticipated to close on or about October 23, 2025.

Key Dates

Recommendation

A substantial insider purchase by a Co-CEO, Director, and 10% owner, particularly in a private placement, is a powerful bullish signal. It suggests that the individual with deep knowledge of the company's operations and future plans believes the stock is significantly undervalued or poised for substantial growth. This level of commitment from a key insider often precedes positive developments and warrants a strong buy recommendation for investors.

Keywords

Summit Therapeutics, SMMT, Robert W. Duggan, insider buying, private placement, common stock, SEC Form 4, beneficial ownership, CEO, director, 10% owner